[go: up one dir, main page]

RS54775B1 - Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini - Google Patents

Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini

Info

Publication number
RS54775B1
RS54775B1 RS20160367A RSP20160367A RS54775B1 RS 54775 B1 RS54775 B1 RS 54775B1 RS 20160367 A RS20160367 A RS 20160367A RS P20160367 A RSP20160367 A RS P20160367A RS 54775 B1 RS54775 B1 RS 54775B1
Authority
RS
Serbia
Prior art keywords
radical
atom
group
alkyl
carbon atoms
Prior art date
Application number
RS20160367A
Other languages
English (en)
Inventor
Branislav Musicki
Jerôme Aubert
Jean-Guy Boiteau
Laurence Clary
Patricia Rossio
Marlène Schuppli-Nollet
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of RS54775B1 publication Critical patent/RS54775B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disupstituisano jedinjenje 3,4-diamino-3-ciklobuten-1,2-diona koje odgovara dole datoj opštoj formuli (I), ili jedna od njegovih farmaceutski prihvatljivih soli ili solvata:u kojoj:R1 predstavlja atom vodonika ili metil,R2 predstavlja prsten koji sadrži pet atoma, izabran od dole datih struktura (1), (2), (3) i (4):u kojima R5, R7a, X i X' imaju dole data značenja,R3 predstavlja aromatični ili heteroaromatični prsten izabran iz grupe koju čine prsteni koji odgovaraju donjim formulama (a) do (o):u kojima R7, R7a, Y i Z imaju dole dato značenje, pri čemu je navedeno da prsteni (a) do (o) mogu opciono imati nekoliko R7 grupa, koje mogu biti identične ili različite, ukupan najviši broj takvih R7 grupa je jedak broju atoma na prstenu koji se mogu supstituisati;R4 predstavlja aromatični ili heteroaromatični prsten izabran iz grupe koju čine prsteni koji odgovaraju dole datim formulama (p) do (z) i (aa) do (ak):u kojima R7, R8, R9, R10, R11, R12, R13, R14 i R15 imaju dole data značenja,R5 predstavlja atom vodnika, atom fluora, alkil radikal koji ima od 1 do 5 ugljenikovih atoma ili fluoroalkil ili perfluoroalkil radikal koji ima od 1 do 5 ugljenikovih atoma,R6 predstavlja atom vodonika, -COOtBu radikal ili -COOBn radikal,R7 predstavlja halogen, ili -R16, -CF3, -COR16, -OR16, -NR16R17, -NO2, -CN, -SO2R16, -SO2NR16R17, -NR16COR17, -CONR16R17, -NR16CO2R17 ili -CO2R16 radikal,R7a predstavlja atom vodonika ili alkil radikal koji ima od 1 do 5 ugljenikovih atoma,R8 predstavlja atom vodonika, atom halogena -OH radikal, ili -SH, -CONHOR16,-CONR16OH, -NR16R17, -SO3H, -OCOR16, -NHSO2R16, -SO2NR16R17, -NHCOR16, -CONR16R17, -NR16CO2R17, -NHS02NR16R17, -CO2R16, pirolil, imidazolil, triazolil ili tetrazolil radikal,R9, R10, R11 i R12 su identični ili različiti i nezavisno su izabrani iz grupe koju čine vodonik, atom halogena i alkil, alkoksi, -CF3, -OCF3, -OH, -NO2, -CN, -SO2R16, -SO2NR16R17, -NR16COR17, -NR16CO2R17, -CONR16R17, -COR16 ili -CO2R16 radikal,ili alternativno, kada dva od R9, R10, R11 i R12 radikala su u orto položaju na aromatičnom ili heteroaromatičnom prstenu izabranom iz grupe koju čine prsteni koji odgovaraju gore datim formulama (p) do (z) i (aa) do (ak), tada oni mogu zajedno obrazovati, sa vezom koja ih spaja, aril, heteroaril, cikloalkil ili heterocikloalkil prsten,R13 i R14 su identični ili različiti, izabrani iz grupe koju čine atom vodonika, atom halogena i alkil, -CF3, -OCF3, -OH, -SH, -CN, -SO2R16, -SO2NR16R17, -NHSO2NR16R17, -NR16R17, -NR16CONR16R17, -NR16COR17, -NR16CO2R17, -CONR16R17, -COR16 ili -CO2R16 radikal,R15 predstavlja atom vodonika ili -OH, -SO2R16, -COR16, -CO2R16, aril, heteroaril, arilalkil, heteroarilalkil, alkil, cikloalkil ili cikloalkilalkil radikal,R16 i R17 su identični ili različiti, izabrani iz grupe koju čine atom vodonika, jedan od sledećih radikala: aril, heteroaril, arilalkil, heteroarilalkil, alkil, fluoroalkil koji ima od 1 do 5 ugljenikovih atoma, cikloalkil ili cikloalkilalkil, i -CH2COOR18 grupa u kojoj R18 predstavlja alkil radikal koji ima od 1 do 5 ugljenikovih atoma,ili alternativno, kada se R16 i R17 nalaze na istom atomu azota, obrazuju heterocikl koji ima između 3 i 7 članova i opciono jedan ili dva heteroatoma izabrana od kiselonika, sumpora i azota pored uobičajenog atoma azota za koji su vezani, pri čemu je moguće da taj heterocikl bude supstituisan sa alkil grupom koja ima od 1 do 5 ugljenikovih atoma ili -COOR18 grupom u kojoj R18 predstavlja alkil radikal koji ima od 1 do 5 ugljenikovih atoma;X i X', koji može biti identičan ili različit, predstavlja atom kiseonika, atom sumpora ili atom azota supstituisan sa R6 radikalom,Y predstavlja atom kiseonika, atom sumpora, ili atom azota supstituisan sa R15 radikalom, iZ predstavlja ugljenikov atom ili azotov atom.Prijava sadrži još 7 patentnih zahteva.
RS20160367A 2011-10-28 2012-10-26 Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini RS54775B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161552940P 2011-10-28 2011-10-28
FR1159833A FR2981935B1 (fr) 2011-10-28 2011-10-28 Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
PCT/FR2012/052478 WO2013061004A1 (fr) 2011-10-28 2012-10-26 Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
EP12791825.8A EP2771329B1 (fr) 2011-10-28 2012-10-26 Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines

Publications (1)

Publication Number Publication Date
RS54775B1 true RS54775B1 (sr) 2016-10-31

Family

ID=45809111

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160367A RS54775B1 (sr) 2011-10-28 2012-10-26 Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini

Country Status (24)

Country Link
US (2) US9388149B2 (sr)
EP (1) EP2771329B1 (sr)
JP (1) JP6068486B2 (sr)
KR (1) KR20140090168A (sr)
CN (1) CN103906738B (sr)
AU (1) AU2012328198A1 (sr)
BR (1) BR112014009889A2 (sr)
CA (1) CA2848263A1 (sr)
CY (1) CY1117705T1 (sr)
DK (1) DK2771329T3 (sr)
ES (1) ES2569053T3 (sr)
FR (1) FR2981935B1 (sr)
HR (1) HRP20160608T1 (sr)
HU (1) HUE029128T2 (sr)
IN (1) IN2014CN02273A (sr)
MX (1) MX342924B (sr)
PL (1) PL2771329T3 (sr)
PT (1) PT2771329E (sr)
RS (1) RS54775B1 (sr)
RU (1) RU2014121390A (sr)
SI (1) SI2771329T1 (sr)
SM (1) SMT201600151B (sr)
WO (1) WO2013061004A1 (sr)
ZA (1) ZA201401678B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563947B2 (ja) 2013-12-02 2019-08-21 ケモセントリックス，インコーポレイティド Ｃｃｒ６化合物
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2020530848A (ja) 2017-08-14 2020-10-29 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
BR112021003956A2 (pt) 2018-09-21 2021-05-25 Pfizer Inc. dioxociclobutenilamino-3-hidróxi-picolinamidas n-substituídas úteis como inibidores de ccr6
PH12022500015A1 (en) 2020-04-30 2023-09-11 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN118215662A (zh) 2021-10-26 2024-06-18 爱杜西亚药品有限公司 Ccr6受体调节剂
TW202325271A (zh) 2021-10-28 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
WO2024222865A1 (zh) * 2023-04-28 2024-10-31 武汉朗来科技发展有限公司 作为ccr6拮抗剂的化合物、其药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652737B2 (en) * 2000-07-21 2003-11-25 Exxonmobil Research And Engineering Company Production of naphtha and light olefins
CN1289471C (zh) * 2001-04-16 2006-12-13 先灵公司 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
AU2008258588B2 (en) * 2007-06-06 2011-11-10 Novartis Ag Anti -inflammatory substituted cyclobutenedione compounds
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
KR200444641Y1 (ko) * 2008-12-03 2009-05-27 강민수 헤드작동형 다기능 스패너
WO2010063802A1 (en) * 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010131145A1 (en) * 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives

Also Published As

Publication number Publication date
WO2013061004A1 (fr) 2013-05-02
US9388149B2 (en) 2016-07-12
ES2569053T3 (es) 2016-05-06
BR112014009889A2 (pt) 2017-04-25
ZA201401678B (en) 2015-04-29
JP2014530894A (ja) 2014-11-20
HUE029128T2 (en) 2017-02-28
CY1117705T1 (el) 2017-05-17
EP2771329A1 (fr) 2014-09-03
SI2771329T1 (sl) 2016-07-29
AU2012328198A1 (en) 2014-04-03
RU2014121390A (ru) 2015-12-10
FR2981935A1 (fr) 2013-05-03
US20160362403A1 (en) 2016-12-15
DK2771329T3 (en) 2016-06-06
CA2848263A1 (fr) 2013-05-02
JP6068486B2 (ja) 2017-01-25
PL2771329T3 (pl) 2016-09-30
CN103906738A (zh) 2014-07-02
US9580412B2 (en) 2017-02-28
WO2013061004A8 (fr) 2014-04-17
FR2981935B1 (fr) 2015-08-07
MX342924B (es) 2016-10-19
IN2014CN02273A (sr) 2015-06-19
EP2771329B1 (fr) 2016-03-16
HRP20160608T1 (hr) 2016-07-01
MX2014003958A (es) 2014-08-27
PT2771329E (pt) 2016-06-17
CN103906738B (zh) 2016-09-07
US20140296254A1 (en) 2014-10-02
KR20140090168A (ko) 2014-07-16
SMT201600151B (it) 2016-07-01

Similar Documents

Publication Publication Date Title
RS54775B1 (sr) Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini
RS54702B1 (sr) Pirazolohinolinski derivati kao inhibitori pde9
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
RS52126B (sr) Derivati azabifenilaminobenzoične kiseline kao inhibitori dehidrogenaze dihidroorotata (dhodh)
RS54708B1 (sr) Ariletinil derivati
RS53939B1 (sr) Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora
NO20053600L (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
RS54199B1 (sr) Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
RS50552B (sr) Derivati pirolopiridina i njihova upotreba kao antagonista crth2
JP2016506369A5 (sr)
JP2013509442A5 (sr)
RS54175B1 (sr) Inhibitori bromodomena i njihova primena
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
ES2620531T3 (es) Inhibidores de la fosfodiesterasa tipo 10A
RS52261B (sr) Amidofenoksi indazoli kao korisni inhibitori c-met-a
EA201390022A8 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
AR059901A1 (es) Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
RS53378B (sr) Jedinjenja sa kondenzovanim prstenom i njihova upotreba
HRP20171273T1 (hr) Spoj dikarboksilne kiseline